MX2010005395A - Metodo para tratar artritis. - Google Patents

Metodo para tratar artritis.

Info

Publication number
MX2010005395A
MX2010005395A MX2010005395A MX2010005395A MX2010005395A MX 2010005395 A MX2010005395 A MX 2010005395A MX 2010005395 A MX2010005395 A MX 2010005395A MX 2010005395 A MX2010005395 A MX 2010005395A MX 2010005395 A MX2010005395 A MX 2010005395A
Authority
MX
Mexico
Prior art keywords
treating arthritis
arthritis
treating
preventing
disclosed
Prior art date
Application number
MX2010005395A
Other languages
English (en)
Inventor
Tariq Ghayur
Philip Bardwell
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2010005395A publication Critical patent/MX2010005395A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Abstract

Se describen métodos para prevenir o tratar artritis.
MX2010005395A 2007-11-16 2008-11-14 Metodo para tratar artritis. MX2010005395A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98847907P 2007-11-16 2007-11-16
PCT/US2008/083478 WO2009064938A1 (en) 2007-11-16 2008-11-14 Method of treating arthritis

Publications (1)

Publication Number Publication Date
MX2010005395A true MX2010005395A (es) 2010-06-02

Family

ID=40291332

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005395A MX2010005395A (es) 2007-11-16 2008-11-14 Metodo para tratar artritis.

Country Status (14)

Country Link
US (2) US20090176785A1 (es)
EP (1) EP2231159A1 (es)
JP (2) JP5450434B2 (es)
KR (1) KR101585848B1 (es)
CN (1) CN101969951B (es)
AU (1) AU2008322595B2 (es)
CA (1) CA2705294C (es)
DO (1) DOP2013000169A (es)
IL (2) IL205501A (es)
MX (1) MX2010005395A (es)
NZ (2) NZ585085A (es)
RU (2) RU2472509C2 (es)
WO (1) WO2009064938A1 (es)
ZA (1) ZA201003434B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP5959501B2 (ja) * 2010-03-25 2016-08-02 アッヴィ・インコーポレイテッド 癌ならびに免疫および自己免疫疾患の治療のためのアポトーシス誘導物質
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
KR20180059560A (ko) 2010-10-29 2018-06-04 애브비 인코포레이티드 아폽토시스―유도제를 포함하는 고체 분산체
RU2628560C2 (ru) 2010-11-23 2017-08-18 Эббви Инк. Соли и кристаллические формы индуцирующего апоптоз агента
DK2642999T3 (en) 2010-11-23 2017-01-09 Abbvie Ireland Unlimited Co METHODS OF TREATMENT FOR USING selectivity-VE BCL-2 INHIBITORS
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
MX2020002032A (es) 2017-08-23 2020-09-17 Guangzhou Lupeng Pharmaceutical Company Ltd Inhibidores de bcl-2.
WO2020041405A1 (en) 2018-08-22 2020-02-27 Newave Pharmaceutical Inc. Bcl-2 inhibitors
US20220073513A1 (en) 2018-12-29 2022-03-10 Newave Pharmaceutical Inc. 1h-pyrrolo[2,3-b]pyridine derivatives and related compounds as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
US20220372042A1 (en) 2019-10-03 2022-11-24 Newave Pharmaceutical Inc. Condensed heterocycles as bcl-2 inhibitors
CN115279375A (zh) 2019-11-05 2022-11-01 艾伯维公司 用于以navitoclax治疗骨髓纤维化和mpn相关病症的给药方案
WO2021133817A1 (en) 2019-12-27 2021-07-01 Guangzhou Lupeng Pharmaceutical Company Ltd. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
EP4110298A1 (en) 2020-02-24 2023-01-04 Guangzhou Lupeng Pharmaceutical Company Ltd. Hot melt extruded solid dispersions containing a bcl2 inhibitor
WO2022140224A1 (en) 2020-12-22 2022-06-30 Newave Pharmaceutical Inc. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
EP0863873B1 (en) * 1995-10-10 1999-11-10 Pfizer Inc. Indole carbamates as leukotriene antagonists
BR0109328A (pt) * 2000-03-21 2003-06-10 Procter & Gamble Inibidores de metaloprotease n-substituìdos, contendo cadeia lateral heterocìclica
ES2318649T3 (es) * 2000-10-20 2009-05-01 EISAI R&D MANAGEMENT CO., LTD. Procedimiento de preparacion de derivados de 4-fenoxi quinolinas.
GB0217431D0 (en) * 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
WO2005012297A1 (en) * 2003-07-28 2005-02-10 Janssen Pharmaceutica N.V. Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
EP1663979B1 (en) * 2003-09-03 2013-10-09 RaQualia Pharma Inc. Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
ES2257929B1 (es) * 2004-07-16 2007-05-01 Laboratorios Del Dr. Esteve, S.A. Derivados de pirazolina, procedimiento para su obtencion y utilizacion de los mismos como agentes terapeuticos.
ES2493466T3 (es) * 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
US20060276464A1 (en) * 2005-05-13 2006-12-07 Wyeth Diarylsulfone sulfonamides and use thereof
WO2008064116A2 (en) * 2006-11-16 2008-05-29 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection

Also Published As

Publication number Publication date
US20090176785A1 (en) 2009-07-09
DOP2013000169A (es) 2013-12-15
JP5667684B2 (ja) 2015-02-12
IL205501A (en) 2013-08-29
JP2014065716A (ja) 2014-04-17
JP2011503199A (ja) 2011-01-27
NZ601350A (en) 2013-08-30
EP2231159A1 (en) 2010-09-29
US20160101109A1 (en) 2016-04-14
CA2705294C (en) 2016-05-17
RU2010123796A (ru) 2011-12-27
KR101585848B1 (ko) 2016-01-15
RU2526201C2 (ru) 2014-08-20
WO2009064938A1 (en) 2009-05-22
CA2705294A1 (en) 2009-05-22
NZ585085A (en) 2012-08-31
WO2009064938A9 (en) 2009-08-06
IL227641A0 (en) 2013-09-30
KR20100099172A (ko) 2010-09-10
RU2472509C2 (ru) 2013-01-20
AU2008322595B2 (en) 2014-01-30
CN101969951B (zh) 2012-10-31
IL205501A0 (en) 2010-12-30
AU2008322595A1 (en) 2009-05-22
CN101969951A (zh) 2011-02-09
JP5450434B2 (ja) 2014-03-26
RU2012143212A (ru) 2014-04-20
ZA201003434B (en) 2011-10-26

Similar Documents

Publication Publication Date Title
MX2010005395A (es) Metodo para tratar artritis.
SG148142A1 (en) Aryloazol-2-yl cyanoethylamino compunds, method of making and method of using thereof
MX2010009765A (es) Moleculas pequeñas que contienen boro como agentes anti-inflamatorios.
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
IN2012DN03883A (es)
MX360301B (es) Moleculas pequeñas que contienen boro como agentes antiinflamatorios.
PH12013502230A1 (en) Multispecific antibodies
WO2009111676A8 (en) Boron-containing small molecules as anti-inflammatory agents
IN2012DN00572A (es)
MX2009005725A (es) Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13.
PT2408718E (pt) Composição à base de hidróxido de cálcio, método para a sua produção e para a sua utilização para o tratamento de águas e lamas
MX2009004030A (es) Articulos antimicrobianos y metodos de fabricacion.
MY150600A (en) Use of opioid antagonists for treating urinary retention
IL200769A (en) A method for processing potash
PL2133402T3 (pl) Sposób obróbki błota defekosaturacyjnego
MX2013007312A (es) Tratamiento con flama de substrato.
EP1988060A4 (en) METHOD FOR TREATING WASTEWATER
EP2164515A4 (en) PROCESS FOR TREATING ATOPIC ECZEMA
BR112012003653A2 (pt) "método de tratar o câncer."
HK1151190A1 (en) Methods of treating scleroderma
WO2011110367A3 (en) Method of screening for htra protease inhibitors useful for prophylaxis and therapy of a bacterial infection
PH12014500538A1 (en) Methods and compositions for treating leukemia
EP2094385A4 (en) METHOD OF WASTE WATER TREATMENT
IN2012DN01846A (es)
MY144317A (en) Treatment of polysilazane waste

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ABBVIE INC.

FG Grant or registration